Cargando…

Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients

BACKGROUND AND OBJECTIVES: Pre-operative kidney volume is an independent predictor of glomerular filtration rate in renal cell carcinoma patients. Compensatory renal growth (CRG) can ensue prior to nephrectomy in parallel to tumor growth and benign parenchyma loss. We aimed to test whether renal met...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenzweig, Barak, Rubinstein, Nimrod D., Reznik, Ed, Shingarev, Roman, Juluru, Krishna, Akin, Oguz, Hsieh, James J., Jaimes, Edgar A., Russo, Paul, Susztak, Katalin, Coleman, Jonathan A., Hakimi, A. Ari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519040/
https://www.ncbi.nlm.nih.gov/pubmed/28727768
http://dx.doi.org/10.1371/journal.pone.0180350
_version_ 1783251573019770880
author Rosenzweig, Barak
Rubinstein, Nimrod D.
Reznik, Ed
Shingarev, Roman
Juluru, Krishna
Akin, Oguz
Hsieh, James J.
Jaimes, Edgar A.
Russo, Paul
Susztak, Katalin
Coleman, Jonathan A.
Hakimi, A. Ari
author_facet Rosenzweig, Barak
Rubinstein, Nimrod D.
Reznik, Ed
Shingarev, Roman
Juluru, Krishna
Akin, Oguz
Hsieh, James J.
Jaimes, Edgar A.
Russo, Paul
Susztak, Katalin
Coleman, Jonathan A.
Hakimi, A. Ari
author_sort Rosenzweig, Barak
collection PubMed
description BACKGROUND AND OBJECTIVES: Pre-operative kidney volume is an independent predictor of glomerular filtration rate in renal cell carcinoma patients. Compensatory renal growth (CRG) can ensue prior to nephrectomy in parallel to tumor growth and benign parenchyma loss. We aimed to test whether renal metabolite abundances significantly associate with CRG, suggesting a causative relationship. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: Tissue metabolomics data from 49 patients, with a median age of 60 years, were previously collected and the pre-operative fold-change of their contra to ipsi-lateral benign kidney volume served as a surrogate for their CRG. Contra-lateral kidney volume fold-change within a 3.3 +/- 2.1 years follow-up interval was used as a surrogate for long-term CRG. Using a multivariable statistical model, we identified metabolites whose abundances significantly associate with CRG. RESULTS: Our analysis found 13 metabolites in the benign (e.g. L-urobilin, Variable Influence in Projection, VIP, score = 3.02, adjusted p = 0.017) and 163 metabolites in the malignant (e.g. 3-indoxyl-sulfate, VIP score = 1.3, adjusted p = 0.044) tissues that significantly associate with CRG. Benign/tumor fold change in metabolite abundances revealed three additional metabolites with that significantly positively associate with CRG (e.g. p-cresol sulfate, VIP score = 2.945, adjusted p = 0.033). At the pathway level, we show that fatty-acid oxidation is highly enriched with metabolites whose benign tissue abundances strongly positively associate with CRG, both pre-operatively and long term, whereas in the tumor tissue significant enrichment of dipeptides and benzoate (positive association), glycolysis/gluconeogenesis, lysolipid and nucleotide sugar pentose (negative associations) sub-pathways, were observed. CONCLUSION: These data suggest that specific biological processes in the benign as well as in the tumor parenchyma strongly influence compensatory renal growth.
format Online
Article
Text
id pubmed-5519040
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55190402017-08-07 Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients Rosenzweig, Barak Rubinstein, Nimrod D. Reznik, Ed Shingarev, Roman Juluru, Krishna Akin, Oguz Hsieh, James J. Jaimes, Edgar A. Russo, Paul Susztak, Katalin Coleman, Jonathan A. Hakimi, A. Ari PLoS One Research Article BACKGROUND AND OBJECTIVES: Pre-operative kidney volume is an independent predictor of glomerular filtration rate in renal cell carcinoma patients. Compensatory renal growth (CRG) can ensue prior to nephrectomy in parallel to tumor growth and benign parenchyma loss. We aimed to test whether renal metabolite abundances significantly associate with CRG, suggesting a causative relationship. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: Tissue metabolomics data from 49 patients, with a median age of 60 years, were previously collected and the pre-operative fold-change of their contra to ipsi-lateral benign kidney volume served as a surrogate for their CRG. Contra-lateral kidney volume fold-change within a 3.3 +/- 2.1 years follow-up interval was used as a surrogate for long-term CRG. Using a multivariable statistical model, we identified metabolites whose abundances significantly associate with CRG. RESULTS: Our analysis found 13 metabolites in the benign (e.g. L-urobilin, Variable Influence in Projection, VIP, score = 3.02, adjusted p = 0.017) and 163 metabolites in the malignant (e.g. 3-indoxyl-sulfate, VIP score = 1.3, adjusted p = 0.044) tissues that significantly associate with CRG. Benign/tumor fold change in metabolite abundances revealed three additional metabolites with that significantly positively associate with CRG (e.g. p-cresol sulfate, VIP score = 2.945, adjusted p = 0.033). At the pathway level, we show that fatty-acid oxidation is highly enriched with metabolites whose benign tissue abundances strongly positively associate with CRG, both pre-operatively and long term, whereas in the tumor tissue significant enrichment of dipeptides and benzoate (positive association), glycolysis/gluconeogenesis, lysolipid and nucleotide sugar pentose (negative associations) sub-pathways, were observed. CONCLUSION: These data suggest that specific biological processes in the benign as well as in the tumor parenchyma strongly influence compensatory renal growth. Public Library of Science 2017-07-20 /pmc/articles/PMC5519040/ /pubmed/28727768 http://dx.doi.org/10.1371/journal.pone.0180350 Text en © 2017 Rosenzweig et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rosenzweig, Barak
Rubinstein, Nimrod D.
Reznik, Ed
Shingarev, Roman
Juluru, Krishna
Akin, Oguz
Hsieh, James J.
Jaimes, Edgar A.
Russo, Paul
Susztak, Katalin
Coleman, Jonathan A.
Hakimi, A. Ari
Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients
title Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients
title_full Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients
title_fullStr Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients
title_full_unstemmed Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients
title_short Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients
title_sort benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519040/
https://www.ncbi.nlm.nih.gov/pubmed/28727768
http://dx.doi.org/10.1371/journal.pone.0180350
work_keys_str_mv AT rosenzweigbarak benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT rubinsteinnimrodd benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT rezniked benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT shingarevroman benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT julurukrishna benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT akinoguz benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT hsiehjamesj benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT jaimesedgara benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT russopaul benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT susztakkatalin benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT colemanjonathana benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients
AT hakimiaari benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients